A senior official from the Biomedical Advanced Research and Development Authority (BARDA) will deliver a keynote address at the 18th annual conference on Superbugs & Superdrugs taking place March 16-17, 2016 in London.
Extending portfolio partnerships to strengthen the antibiotic pipeline will be the topic of the exclusive address from Dr. Christopher Houchens, the Project Manager of BARDA’s Anti-Infective Program. Houchens will provide case studies on current partnerships and address BARDA’s efforts to combat antibiotic resistant infections. Attendees will also learn about BARDA funding opportunities and future research collaborations.
Other confirmed participants include leading executive stakeholders from pharma, government, and not-for-profit organizations. The popularity of the event highlights the imminent global threat of antimicrobial resistance and the urgency for scientists and drug developers to discover new alternatives to bacteria resistant treatments.
Prabhavathi Fernandes, Cempra Pharmaceuticals President & CEO, will explore international collaboration for successful worldwide commercialization; Line Matthiessen, Head of the European Commision’s Unit on Fighting Infectious Diseases and Advancing Public Health, will deliver the latest updates on EU’s action plan on AMR and public private partnerships; and Jean-Pierre Paccaud, Director of Business Development and Legal from Drugs for Neglected Diseases Initiative (DNDi), will delve further into global product development partnerships to foster new antibiotic treatments and discuss their responsible use.
The full agenda will feature 20 thought-provoking presentations from leading pharmaceutical organizations and industry experts; spotlight sessions on industry incentive and partnerships; progressive insight into drug discovery; best practices in antimicrobial stewardship; and topical panel debates to both new and seasoned stakeholders.
Global Biodefense is an official media partner of Superbugs & Superdrugs 2016.
